Is IDRSF or NOBL a better dividend investment in 2026?

IDRSF currently yields 48.90% with a 5% 5-year dividend growth rate. NOBL yields 2.14% with 5% growth. The better choice depends on your goal: IDRSF offers higher current income.

What is the dividend yield difference between IDRSF and NOBL?

IDRSF has a forward dividend yield of 48.90% ($2.00/share annually). NOBL yields 2.14% ($2.27/share annually). The yield gap is 46.76 percentage points.

Home › Compare › IDRSF vs NOBL

IDRSF vs NOBL: Dividend Comparison 2026

IDRSF yields 48.90% · NOBL yields 2.14%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 IDRSF wins by $349.4K in total portfolio value

INVESTMENT

TIME HORIZON10 years

IDRSF

● Live price

48.90%

Share price

$4.09

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$372.2K

Annual income

$74,100.38

Full IDRSF calculator →

NOBL

● Live price

2.14%

Share price

$106.01

Annual div

$2.27

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$22.8K

Annual income

$246.19

Full NOBL calculator →

Portfolio growth — IDRSF vs NOBL

📍 IDRSF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	IDRSF	NOBL
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, IDRSF + NOBL cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

IDRSF pays

NOBL pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IDRSF

Annual income on $10K today (after 15% tax)

$4,156.48/yr

After 10yr DRIP, annual income (after tax)

$62,985.32/yr

NOBL

Annual income on $10K today (after 15% tax)

$182.19/yr

After 10yr DRIP, annual income (after tax)

$209.26/yr

At 15% tax rate, IDRSF beats the other by $62,776.06/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IDRSF + NOBL for your $10,000?

IDRSF: 50%NOBL: 50%

100% NOBL50/50100% IDRSF

Portfolio after 10yr

$197.5K

Annual income

$37,173.28/yr

Blended yield

18.82%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on IDRSF right now

IDRSF

Analyst Ratings

Buy

Hold

Consensus: Buy

Altman Z

-10.1

Piotroski

3/9

NOBL

No analyst data

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IDRSF buys

NOBL buys

No recent congressional trades found for IDRSF or NOBL in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricIDRSFNOBL

Forward yield	48.90% ✓	2.14%
Annual dividend / share	$2.00	$2.27 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$372.2K ✓	$22.8K
Annual income after 10y	$74,100.38 ✓	$246.19
Total dividends collected	$295.4K ✓	$2.3K
Payment frequency	quarterly	quarterly
Sector	Stock	ETF

Year-by-year: IDRSF vs NOBL ($10,000, DRIP)

Year	IDRSF Portfolio	IDRSF Income/yr	NOBL Portfolio	NOBL Income/yr	Gap
1← crossover	$15,590	$4,889.98	$10,914	$214.34	+$4.7K → IDRSF
2	$23,806	$7,124.73	$11,897	$218.63	+$11.9K → IDRSF
3	$35,640	$10,167.77	$12,952	$222.72	+$22.7K → IDRSF
4	$52,361	$14,226.41	$14,086	$226.62	+$38.3K → IDRSF
5	$75,560	$19,533.63	$15,302	$230.33	+$60.3K → IDRSF
6	$107,194	$26,344.00	$16,607	$233.85	+$90.6K → IDRSF
7	$149,625	$34,927.92	$18,007	$237.18	+$131.6K → IDRSF
8	$205,663	$45,564.28	$19,508	$240.35	+$186.2K → IDRSF
9	$278,591	$58,531.92	$21,116	$243.35	+$257.5K → IDRSF
10	$372,193	$74,100.38	$22,841	$246.19	+$349.4K → IDRSF

IDRSF vs NOBL: Complete Analysis 2026

IDRSF — Stock

Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.

Full IDRSF Calculator →

NOBL — ETF

The fund will invest at least 80% of its total assets in component securities of the index. The index contains a minimum of 40 stocks, which are equally weighted, and no single sector is allowed to comprise more than 30% of the index weight. It seeks to remain fully invested at all times in securities and/or financial instruments that, in combination, provide exposure to the returns of the index without regard to market conditions, trends or direction.

Full NOBL Calculator →

📬

Get this IDRSF vs NOBL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IDRSF vs SCHD IDRSF vs JEPI IDRSF vs O IDRSF vs KO IDRSF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.